Apricus Biosciences   Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (1987)
Status: Acquired by Seelos Therapeutics (2019)

Organization Overview

First Clinical Trial
2005
NCT00691184
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NexMed, Inc. | NexMed (U.S.A.), Inc. | NEXMED (U.S.A.), Inc. | NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)

Active Ingredients

Drugs in Phase 2 Trials (2)

alprostadil (prostin) (1 trial)

fispemifene (1 trial)

Drugs in Phase 1 Trials (1)

terbinafine (lamisil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Erectile Dysfunction (Phase 2)

Hypogonadism (Phase 2)

Neoplasm Metastasis (Phase 2)

Onycholysis (Phase 1)

Onychomycosis (Phase 1)

Raynaud Disease (Phase 2)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 2)

Tinea Pedis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3